On January 7, 2022 Adocia reported that invites you to meet management team members available for virtual meetings: Gérard Soula (CEO), Olivier Soula (Deputy General Manager) and Valérie Danaguezian (Chief Financial Officer) (Press release, Adocia, JAN 7, 2022, View Source [SID1234598436]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

• 25th ODDO BHF Forum

Date: January 6-11, 2022

Link: View Source

• French Delegation @ JP Morgan Healthcare Conference

Date: January 10-13, 2022

Link: View Source

• Biotech Showcase

Date: January 10-12 & 17-19, 2022

Link: https://informaconnect.com/biotech-showcase/?gclid=Cj0KCQiA8ICOBhDmARIsAEGI6o31OJhl9HkuWr0UvHw6OxlXr3i2J42j_-dvnYmiyuhzE7r7Mr_pYRUaAlNBEALw_wcB

• H.C. Wainwright BIOCONNECT Virtual 2022 Conference

Date: January 10-13, 2022

Link: View Source

On January 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, reported that CEO, Dr James Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from 10-13 January 2022 (Press release, Kazia Therapeutics, JAN 7, 2022, https://www.prnewswire.com/news-releases/kazia-therapeutics-to-present-at-hc-wainwright-bioconnect-conference-301455376.html [SID1234598431]). The company has been invited to participate via a ‘fireside chat’ with a senior equity research analyst at the bank.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The HC Wainwright BioConnect Conference brings together more than 275 presenting companies from the life sciences sector, along with invited speakers and panellists. This year’s keynote speakers include Scott Gottlieb, MD, who was Commissioner of the Food and Drug Administration (FDA) between 2017 and 2019.

Dr Garner will participate in a fireside chat with Sean Lee, an equity research analyst at HC Wainwright. Dr Garner’s interview will be available via online streaming at the conference event platform from 7am (ET) on Monday, January 10, 2022. The interview is expected to cover an update on Kazia’s significant progress in 2021, and a discussion of the rich milestones anticipated in 2022.

Registration to the conference is free and is available via the conference website at:-

View Source

On January 7, 2022 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, reported that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022 (Press release, CNS Pharmaceuticals, JAN 7, 2022, https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-hc-wainwright-bioconnect-conference-301456183.html [SID1234598430]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, January 10, 2022, at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company’s website (www.cnspharma.com). The webcast replay will be archived for 90 days following the event.

On January 7, 2022 Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, reported that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held January 10–13, 2022 (Press release, Palatin Technologies, JAN 7, 2022, https://www.prnewswire.com/news-releases/palatin-to-present-at-hc-wainwright-bioconnect-conference-301456337.html [SID1234598429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Carl Spana, PhD, President and Chief Executive Officer will provide an update on the Company’s pipeline, including the ongoing pivotal Phase 3 MELODY-1 study of PL9643 in patients suffering from dry eye disease.

The Company’s presentation will be available for on demand listening beginning at 7:00 a.m. ET on Monday, January 10, 2022, through the H.C. Wainwright BioConnect conference portal.

To request a one-on-one meeting with Palatin during the conference, please contact your H.C. Wainwright representative or email [email protected].

On January 7, 2022 Nordic Nanovector ASA (OSE: NANOV) reported that provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL) (Press release, Nordic Nanovector, JAN 7, 2022, View Source [SID1234598427]). The Company reports that 106 patients have been enrolled into PARADIGME as of 6 January 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Given the ongoing impact from the SARS-CoV-2 omicron variant on patient recruitment, the Company now anticipates the preliminary three-month data readout from PARADIGME to be reported during the second half of 2022 (previously first half of 2022).

As communicated on 3 August 2021, the changes to the PARADIGME protocol and other initiatives implemented by the Company have positively impacted execution of the PARADIGME trial. However, the ongoing COVID pandemic, exacerbated by the rapid spread of the new omicron variant of SARS-COV-2, has continued to affect the Company’s ability to screen, enrol and treat new patients whose physical condition means they are at the greatest risk from COVID-19 infection.

Despite this challenging situation, Nordic Nanovector continues to work diligently towards the completion of PARADIGME, which remains the Company’s key strategic priority for 2022.

Erik Skullerud, Chief Executive Officer of Nordic Nanovector, commented: "We are experiencing an unexpected significant impact of the new SARS-CoV-2 omicron variant on the enrolment rate of our clinical trial. However, we now have the end in sight, and I am confident that we can deliver the important preliminary data from this study during the second half of 2022."